Business

Biotech, pharma, and money in science

Limbix Anxiety Tech Bar Scene
Business

The opportunity ‘is huge’: Why tech developers are trying to tackle mental health

By Rebecca Robbins

STAT Live

Archived: A chat to discuss Amazon’s pivot into health care

By Casey Ross and Ike Swetlitz

Atul Listening Tour
Business

CEO Gawande’s first task: a road trip to hear firsthand about workers’ health challenges

By Casey Ross and Orly Nadell Farber

Lessons Learned
Lessons Learned

Lessons Learned: This is how you leave academics, start a company, and then come back again

By Megha Satyanarayana

Marijuana Microbe
Business

Q&A: This Mass. company says it can sniff out microbes on marijuana

By Kate Sheridan

Amarin Transcript
Biotech

Archived chat: Breaking down Amarin’s highly anticipated REDUCE-IT trial

By Adam Feuerstein

Ankit Mahadevia Spero
Biotech

Boston-area companies bet on antibiotic development, even as big drug makers step back

By Kate Sheridan

Business

Join our subscriber-only chat on July 19: Amazon’s pivot into health care.

By STAT

Health

No more ‘sledgehammer’: As gonorrhea grows resistant to antibiotics, researchers look to bespoke treatments

By Helen Branswell

Politics

PhRMA responds to Trump blueprint with its own drug-pricing proposal: Reduce payments to PBMs

By Ike Swetlitz

Amazon PBM shopping
Business

In prescription drug business, will Amazon partner with PBMs, or seek to conquer them?

By Casey Ross

Biotech

Novartis is the implied villain of the most popular film in China right now

By Rebecca Robbins

Joseph Jimenez Profile
Politics

Novartis, Michael Cohen contacts were more extensive than previously disclosed

By Ed Silverman and Ike Swetlitz

Atul Gawande Brigham and Women's Hospital
First Opinion

Health care needs more physician CEOs like Atul Gawande

By Alexi Nazem

Ian Read Profile
Heavyweights

How Pfizer’s CEO flew under the political radar with price hikes — until he tangled with Trump

By Ed Silverman and Kate Sheridan

Biotech

Zogenix to submit anti-seizure drug for approval after clinical trial confirms benefit

By Adam Feuerstein

Generic Influenza
Biotech

Otsuka Pharma signs $430m deal to buy Visterra and its antibody therapies

By Jonathan Saltzman — Boston Globe

Kim Kardashian
Pharmalot

A drug maker paid Kim Kardashian $500,000 for a few social media posts. Were they worth it?

By Ed Silverman

Celgene
Adam's Take

Celgene is perking up. Here’s what needs to happen for the momentum to continue

By Adam Feuerstein

Adam's Take

Red flags fly over Anavex: What’s stopping the drug maker from enrolling U.S., European patients in trials?

By Adam Feuerstein

Human T lymphocyte
Biotech

Seeking to unleash immunotherapies on solid tumors, biotech homes in on cell receptors

By Andrew Joseph

Biotech

The biotech scorecard for the third quarter: 12 make-or-break industry events to watch

By Adam Feuerstein and Damian Garde

Anatomical heart
In the Lab

Bayer teams up with the Broad to tackle congestive heart failure

By Jonathan Saltzman — Boston Globe

Amazon Pharma Future
Business

Amazon is taking on health care’s most vexing challenge — the chronically ill

By Casey Ross

Acceleron Blood Disorders
Biotech

Acceleron blood disease drug hits goal in pivotal clinical trial

By Adam Feuerstein

STAT Live

Archived chat: STAT on Marijuana-based medicine and drug development

By Andrew Joseph

PillPack Co-Founders
Business

Amazon’s acquisition of PillPack is a first step, but not a fatal blow for the pharmacy industry

By Casey Ross

Blood tests - vials
Biotech

Department of Defense funds biotech making blood platelets from stem cells

By Jonathan Saltzman — Boston Globe

Pill pack
Pharmalot

Amazon agrees to buy PillPack in a bid to remake the pharmaceutical supply chain

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy